HB543
Log in to followAN ACT relating to the use of experimental treatments for life-threatening or severely debilitating illness.
Create a new section of KRS Chapter 217 to define terms; permit a manufacturer operating within an eligible facility to make available to an eligible patient an individualized investigational drug, biological product, or device; permit the manufacturer to provide the individualized investigational drug, biological product, or device or require the patient to cover the costs; provide that if a patient dies while being treated his or her heirs are not liable for costs; provide that…
Introduced: February 3, 2026
Last action: February 10, 2026
Plain-language summary
This bill would allow manufacturers to make experimental drugs, biological products, or devices available to patients with life-threatening or severely debilitating illnesses before those treatments have received full approval. It sets out rules about who may access these treatments, how costs are handled, and protections for doctors who recommend them and manufacturers who provide them with reasonable care. It also clarifies that insurers would not be required to cover these treatments and hospitals would not…
Bill Text Versions
Legislative History
Primary Sponsor
